US Stock Movement: Xeris Biopharma surged on October 5th due to acquisition interest, Phase III results for XP-8121, and revenue growth
Bitget异动解读2026/10/05 16:30Xeris Biopharma's Significant Surge on October 5 Explained
Keywords: acquisition interest, XP-8121 Phase III, revenue growth
1. On September 29, it was reported that H Lundbeck had been working with advisors to evaluate the possibility of acquiring Xeris. The discussions remain in the preliminary stages; Xeris stated that the company is "not for sale" and will continue to develop and commercialize its therapeutic product portfolio.
2. On September 9, the company stated that the registrational Phase III study plan for XP-8121 is scheduled to commence on time at the end of 2026, with primary results expected to be announced in the second half of 2028. FDA approval and commercialization in the United States is anticipated for 2030, with peak net revenue potential estimated between $1 billion and $3 billion.
3. On August 6, the company announced total revenue of $92.1 million for the second quarter, a 29% year-on-year increase; net product revenue reached $91 million, a 34% year-on-year increase. Among these, Recorlev’s net revenue was $56.8 million, up 81% year-on-year, and full-year total revenue guidance for 2026 was adjusted to $385 million to $390 million.
(Disclaimer: This content is generated by AI technology based on the summary of publicly available information, for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
New York oil prices closed down 1.84%, Brent fell 1.89%
At the close of the day, the price of light crude oil futures for November delivery on the New York Mercantile Exchange fell by $1.68 to $89.43 per barrel, a decrease of 1.84%. The price of Brent crude oil futures for December delivery in London dropped by $1.93, settling at $100.32 per barrel, a decline of 1.89%.
WTI crude oil falls below $89 per barrel, down 2.33% intraday
WTI crude oil prices have fallen below $89 per barrel, marking a 2.33% drop for the day. Recent international oil price fluctuations have been influenced by multiple factors, including supply and demand expectations, global macroeconomic trends, and geopolitical developments—all of which could impact future oil price movements. The direction of crude oil prices will continue to depend on the dynamic changes in these elements.
Brent crude oil falls below $100 per barrel, down 2.2% intraday
Brent crude oil prices have fallen below the $100 per barrel mark, with an intraday drop of 2.20%. As a key benchmark for international oil prices, fluctuations in Brent crude prices often trigger chain reactions across the global energy market, transportation costs, and the profit margins of various industrial supply chains. This recent price decline has also sparked widespread market attention regarding the future supply and demand dynamics of crude oil and the overall trend of international commodities.
Crypto prices
More
